Given the current data on the efficacy and safety of budesonide rectal
Ulcerative colitis (UC), In this study, the impact of baseline use of oral 5
10
Its use in ulcerative colitis (UC) was limited to rectal preparations until recently when the new oral budesonide formulation incorporating the multi-matrix system technology was introduced
Budesonide MMX at the dose of 9 mg/day for 8 weeks is effective and safe in inducing clinical and endoscopic remission in patients with mild to moderate UC, who had an inadequate response or were intolerant to either first line conventional therapy with topical and oral 5-aminosalicylic acid
We performed 2 randomized, phase 3 trials to evaluate the ability of budesonide rectal foam, formulated to optimize retention and provide uniform delivery of budesonide to the rectum and distal
Context and Policy Issues
Post-marketing surveillance is underway to assess the real-world outcomes in UC patients
Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis
Safety and efficacy have not been established
Budesonide foam vs
The aim of this study was to evaluate the cost-effectiveness of budesonide MMX versus commonly used
2 The studies enrolled 546 patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis extending at least 5 cm, but no more than 40 cm, from
Budesonide rectal foam formulation is for rectal administration only, and it contains 2 mg of budesonide per one metered dose